RxDoctor Payments Data

Emad Elbadawy, MD

Internal Medicine · Cleveland, OHNPI 1104892801

Payments from drug & device makers

$10,045in general payments, 2019–2025

Across 660 payments — averaging $15.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Lilly USA, LLC$872
  • AstraZeneca$815
  • Amgen$731
  • Teva Pharmaceuticals USA, Inc.$404
  • Nestle Healthcare Nutrition Inc.$392
  • plus $6K from 51 others

What the payments were for

  • Food & beverage$9,95699%
  • Education$881%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)83$1,108
Lilly USA, LLC72$872
AstraZeneca42$815
Amgen47$731
Teva Pharmaceuticals USA, Inc.30$404
Nestle Healthcare Nutrition Inc.25$392
Pfizer29$380
Exact Sciences17$375
GSK25$373
Novo Nordisk24$337
Johnson & Johnson25$325
Sunovion Pharmaceuticals Inc.22$323
Novartis16$236
Amarin Pharma, Inc.16$232
Astellas Pharma US Inc16$229
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC16$225
Biohaven Pharmaceutical Holding Company Ltd.21$213
Bayer13$181
Otsuka America Pharmaceutical, Inc.9$180
Aimmune Therapeutics, Inc.7$159
Sanofi-aventis U.S. LLC8$144
Evoke Pharma, Inc.8$132
Dexcom, Inc.6$130
Merck7$113
Xeris Pharmaceuticals, Inc.6$106
Vivus LLC5$106
UCB, Inc.5$99
Neurocrine Biosciences, Inc.4$89
Abbott4$84
Coloplast1$84
Lundbeck LLC3$69
Scpharmaceuticals Inc.3$65
Sumitomo Pharma America, Inc.7$61
Biohaven Pharmaceuticals, Inc.3$59
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)3$54
Mannkind Corporation3$49
Gilead2$49
Mylan Specialty L.p.3$46
Eisai Inc.3$40
Melinta Therapeutics, LLC2$36
Boehringer Ingelheim2$34
Ultragenyx Pharmaceutical Inc.1$28
Scilex Pharmaceuticals Inc.2$27
Viatris Specialty LLC1$27
Axsome Therapeutics, Inc.1$25
Smith+Nephew1$24
Otsuka Pharmaceutical Development & Commercialization, Inc.1$20
Kowa Pharmaceuticals America, Inc.1$19
E.r. Squibb & Sons, L.L.C.1$19
Corcept Therapeutics1$18
Avanir Pharmaceuticals, Inc.1$17
Agios Pharmaceuticals, Inc.1$17
Indivior Inc.1$14
Bsn Medical Inc1$14
Hikma Pharmaceuticals USA1$13
Eyevance Pharmaceuticals LLC1$13
Jazz Pharmaceuticals Inc.1$12

How this compares

$10,045 in reported general payments places this provider in the 90th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$249,517
Medicare patients
720
Services billed
2,980

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,828$685,001
XareltoRivaroxaban360$140,561
IngrezzaValbenazine Tosylate12$96,653
JardianceEmpagliflozin266$95,648
NuedextaDextromethorphan Hbr/Quinidine99$91,682
JanuviaSitagliptin Phosphate250$82,531
OzempicSemaglutide59$68,930
XifaxanRifaximin38$68,030
Divalproex Sodium954$57,001
EntrestoSacubitril/Valsartan160$56,097
MyrbetriqMirabegron165$55,863
TrulicityDulaglutide65$53,529
Atorvastatin Calcium3,408$51,551
Trelegy ElliptaFluticasone/Umeclidin/Vilanter81$51,404
Risperidone ErRisperidone Microspheres46$49,138

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Nurtec Odt$380$710,4271,852 claims
Johnson & JohnsonXarelto, Invega Sustenna$325$180,878371 claims
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat$34$155,242396 claims
Neurocrine Biosciences, Inc.Ingrezza$89$96,65312 claims
Avanir Pharmaceuticals, Inc.Nuedexta$17$91,68299 claims
MerckJanuvia$113$82,531250 claims
GSKTrelegy Ellipta, Breo Ellipta$373$77,403142 claims
Novo NordiskOzempic$337$68,93059 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$225$68,03038 claims
NovartisEntresto$236$56,097160 claims
Astellas Pharma US IncMyrbetriq$229$55,863165 claims
Lilly USA, LLCTrulicity$872$53,52965 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →